Results vary depending on starting weight, medication suitability, dose tolerance, lifestyle habits, and consistency
It is approved by the FDA and EMA to support weight loss in people with BMI 30 kg/m 2 or 27 kg/m 2 and obesity-related co-morbidity [9, 17]
The department also did not provide a date for the launch of the new regional obesity management service, which had been due to open in early 2026
How SMGT-GLP-1 Transforms Your Health SMGT-GLP-1 is a multi-functional treatment with proven benefits in: Weight Loss Suppresses appetite, slows gastric emptying, and promotes fat burning
While these actions are similar to those of GLP-1 analogs like Wegovy and Zepbound, there is some evidence that, compared to GLP-1 drugs, amylin analogs are better tolerated and help preserve lean muscle mass
Some patients may begin to see results in five weeks, while it may take up to 3 months for others